Editas Competitors

Stocks . USA . 
Stock . Editas Medicine
EDIT Stock  USD 2.76  0.03  1.10%   
Editas Medicine competes with Beam Therapeutics, Crispr Therapeutics, Caribou Biosciences, Verve Therapeutics, and Intellia Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Editas Medicine competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Editas Medicine to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Editas Medicine Correlation with its peers.
For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Editas Medicine competition on your existing holdings.
  
Build AI portfolio with Editas Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.142.769.02
Details
Intrinsic
Valuation
LowRealHigh
0.122.488.74
Details
Naive
Forecast
LowNextHigh
0.062.769.03
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.332.753.17
Details

Editas Medicine Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Editas Medicine and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Editas and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Editas Medicine does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SANA
+ 0.96
CRBU
PRME
+ 0.95
CRSP
SANA
+ 0.94
CRSP
CRBU
+ 0.93
CRSP
NTLA
+ 0.9
CRSP
PRME
+ 0.89
NTLA
  
High negative correlations   
ALLO
- 0.26
CRBU
ALLO
- 0.23
DNA
ALLO
- 0.21
NTLA
SANA
- 0.17
ALLO
ALLO
- 0.14
CRSP
ALLO
- 0.13
VERV

Risk-Adjusted Indicators

There is a big difference between Editas Stock performing well and Editas Medicine Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Editas Medicine's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BEAM  2.82  0.06  0.03  0.16  4.33 
(2.85)
 5.84 
(4.15)
 24.20 
CRSP  2.94  0.93  0.24  6.04  2.96 
(3.57)
 7.09 
(4.35)
 16.14 
CRBU  5.47  1.55  0.26  1.19  4.86 
(6.78)
 12.02 
(8.49)
 23.18 
VERV  4.86  1.73  0.40  5.80  3.13 
(6.92)
 8.49 
(5.62)
 83.78 
NTLA  4.04  0.57  0.10  0.45  5.48 
(4.31)
 8.49 
(5.29)
 36.46 
PRME  6.92  1.88  0.30  1.10  5.83 
(8.94)
 21.58 
(10.81)
 41.91 
VRTX  1.31 (0.18) 0.00 (0.05) 0.00 
 0.00 
 2.70 
(2.51)
 12.74 
DNA  4.18  0.44  0.12  0.38  4.34 
(4.84)
 11.44 
(7.43)
 29.69 
ALLO  3.64 (0.31) 0.00 (0.03) 0.00 
 0.00 
 9.09 
(5.11)
 32.96 
SANA  4.83  1.81  0.45  1.99  3.18 
(6.54)
 12.50 
(6.22)
 31.62 
All Fundamental Data

Editas Medicine Competitive Analysis

The better you understand Editas Medicine competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Editas Medicine's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Editas Medicine's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EDIT BEAM CRSP CRBU VERV NTLA PRME VRTX DNA ALLO
 1.10 
 2.76 
Editas
 1.47 
 20.75 
Beam
 18.22 
 65.13 
Crispr
 12.02 
 2.05 
Caribou
 0.37 
 10.91 
Verve
 1.94 
 12.06 
Intellia
 5.90 
 4.13 
Prime
 0.75 
 459.81 
Vertex
 3.79 
 10.13 
Ginkgo
 0.81 
 1.25 
Allogene
Market Volatility
(90 Days Market Risk)
Dangerous
Not too volatile
Very steady
Very risky
Relatively risky
Somewhat reliable
Very risky
Very steady
Moderately volatile
Very risky
Market Performance
(90 Days Performance)
Solid
Modest
Solid
Solid
Good
Good
Solid
Very Weak
OK
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Average
Low
Low
Below Average
Low
Below Average
Below Average
Low
Quite High
Quite High
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Sell
Strong Hold
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Strong Hold
Sell
Sell
Current Ratio
12.67
4.64
17.57
12.23
11.55
7.24
6.7
4.7
11.84
11.42
Net Asset
341.59 M
1.1 B
2.24 B
313.31 M
647.39 M
1.19 B
297.51 M
22.53 B
1.38 B
548.71 M
Profit Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.0891
-1.99
N/A
EBITDA
(231.28 M)
(383.98 M)
(447.31 M)
(166.62 M)
(221.91 M)
(523.98 M)
(196.34 M)
486.3 M
(484.39 M)
(243.33 M)
Operating Margin
-7.58
-15.97
-171.59
-18.24
-1.11
-7.27
-36.03
0.37
-1.82
N/A
Current Valuation
48.75 M
907.08 M
3.24 B
(32.5 M)
555.78 M
804.64 M
532.36 M
114.65 B
469.59 M
72.48 M
Price To Book
3.82
1.9
2.66
0.69
2.08
1.52
5.2
7.35
0.9
0.7
Retained Earnings
(1.47 B)
(1.57 B)
(1.37 B)
(448.39 M)
(743.01 M)
(2.18 B)
(687.21 M)
9.61 B
(5.84 B)
(1.82 B)
Current Asset
144.99 M
2.89 B
232 M
N/A
N/A
77.63 M
N/A
1.41 B
10.07 B
418.72 M
One Year Return
N/A
N/A
N/A
N/A
N/A
N/A
-0.31
N/A
N/A
N/A
Beta
2.1
2.08
1.74
2.44
1.68
2.13
1.55
0.42
1.26
0.31
Number Of Employees
246
393
393
147
274
403
214
6.1 K
834
226
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
N/A
99.55
N/A
N/A
N/A
Shares Outstanding
83.71 M
100.56 M
86.36 M
93 M
89.31 M
103.58 M
134.5 M
256.8 M
46.34 M
218.73 M
Three Year Return
N/A
N/A
N/A
N/A
N/A
N/A
3.82
N/A
N/A
N/A
Cash Flow From Operations
(210.28 M)
(347.25 M)
(142.77 M)
(138.2 M)
(157.69 M)
(348.88 M)
(122.86 M)
(492.6 M)
(319.58 M)
(200.3 M)
Total Debt
35.03 M
161.43 M
223.69 M
26.49 M
69.98 M
210.2 M
40.79 M
1.75 B
467.73 M
90.76 M
Return On Equity
-1.41
-0.38
-0.2
-0.53
-0.34
-0.58
-1.15
-0.0564
-0.58
-0.6
Return On Asset
-0.37
-0.19
-0.13
-0.29
-0.19
-0.3
-0.4
0.12
-0.17
-0.29
Number Of Shares Shorted
8.73 M
24.08 M
25.54 M
6.19 M
9.89 M
30.13 M
20.14 M
4.39 M
11.31 M
26.57 M
Book Value Per Share
0.75
11.52
21.18
2.34
5.33
7.53
0.84
64.2
11.84
1.76
Current Liabilities
6.92 M
706.6 M
78 M
N/A
N/A
10.7 M
N/A
506.35 M
3.1 B
26.36 M
Total Asset
341.59 M
1.1 B
2.24 B
313.31 M
647.39 M
1.19 B
297.51 M
22.53 B
1.38 B
548.71 M
Debt To Equity
0.043
0.25
0.12
0.08
0.003
0.079
0.18
0.063
0.032
0.13
Short Ratio
4.26
12.99
9.74
9.39
5.92
5.61
7.36
2.78
10.64
7.91
Target Price
3.38
44.07
81.75
9.14
15.11
37.3
8.39
499.87
8.67
8.15
Shares Owned By Institutions
57.56
98.06
76.46
53.3
94.79
97.03
56.84
97.63
79.34
80.54
Market Capitalization
228.54 M
2.09 B
4.76 B
190.66 M
984.22 M
1.25 B
555.47 M
118.08 B
571.27 M
273.41 M
Price To Earning
-7.02
37.48
17.33
N/A
5.45
-19.91
14.4
24.57
25.51
-3.3
Price To Earnings To Growth
N/A
-2.3
-0.21
0.5
N/A
-0.0969
N/A
0.58
N/A
-4.18
Price To Sales
6.38
32.82
126.28
19.22
16.41
27.41
144.43
10.64
2.41
11631.14
Net Income
(237.09 M)
(376.74 M)
(366.25 M)
(149.1 M)
(198.71 M)
(519.02 M)
(195.88 M)
(535.6 M)
(547.03 M)
(257.59 M)
Earnings Per Share
-3.04
-4.61
-4.49
-1.62
-2.11
-5.23
-1.61
-3.82
-8.91
-1.22
Shares Owned By Insiders
0.33
1.22
1.68
9.82
5.1
4.98
24.21
0.14
6.87
17.74
Revenue
32.31 M
63.52 M
35 M
9.99 M
32.33 M
57.88 M
2.98 M
11.02 B
227.04 M
22 K
Working Capital
212.09 M
696.08 M
1.85 B
188.73 M
499.84 M
529.01 M
173.93 M
6.03 B
495.48 M
267.86 M
Cash And Equivalents
452.56 M
1.09 B
2.07 B
339.92 M
293.56 M
874.28 M
146.66 M
9.77 B
1.32 B
490.49 M
Cash Per Share
6.59
15.9
26.48
5.59
4.9
11.5
6.39
38.06
0.84
3.41
Gross Profit
(161.41 M)
(302.07 M)
(400.08 M)
(119.76 M)
(150.82 M)
(417.32 M)
(151.57 M)
5.89 B
190.02 M
(190.24 M)
Day Typical Price
2.76
20.96
63.54
2.01
10.93
12.16
4.07
461.65
10.12
1.28
Accumulation Distribution
0.0732
0.0603
0.11
0.14
0.0082
0.055
0.0692
0.019
0.0632
0.0815
Market Facilitation Index
0.21
1.31
7.49
0.29
0.09
0.69
0.29
8.86
0.66
0.11
Daily Balance Of Power
0.1429
0.229
1.340454
0.7586
(0.44)
0.3333
0.7931
(0.39)
0.5606
0.0909
Period Momentum Indicator
0.03
0.3
10.04
0.22
(0.04)
0.23
0.23
(3.46)
0.37
0.01
Rate Of Daily Change
1.01
1.01
1.18
1.12
1.0
1.02
1.06
0.99
1.04
1.01
Day Median Price
2.77
21.07
62.75
1.99
10.95
12.21
4.05
462.57
10.11
1.3
Price Action Indicator
0.01
(0.16)
7.4
0.17
(0.06)
(0.03)
0.2
(4.49)
0.21
(0.04)
Relative Strength Index
65.48
60.33
74.39
62.52
80.37
62.06
84.91
56.47
64.0
40.32
Coefficient Of Variation
455.85
1415.9
436.61
384.12
628.46
694.74
416.07
(4,607)
844.86
(9,865)
Mean Deviation
5.05
2.82
2.94
5.47
4.86
4.04
6.92
1.31
4.18
3.64
Jensen Alpha
1.02
0.0587
0.935
1.55
1.73
0.569
1.88
(0.18)
0.4377
(0.31)
Total Risk Alpha
0.4868
(0.30)
0.3653
0.7975
0.2037
0.0121
0.886
(0.32)
(0.13)
(0.83)
Sortino Ratio
0.2353
0.034
0.2423
0.2552
0.4028
0.1049
0.2979
N/A
0.1153
N/A
Downside Variance
27.46
21.99
11.59
39.62
16.58
41.18
45.34
N/A
21.58
N/A
Standard Deviation
6.26
4.25
4.22
6.71
11.19
5.65
8.93
1.93
5.71
5.44
Kurtosis
(0.13)
7.68
4.69
(0.57)
43.54
4.46
0.5394
10.66
1.42
4.24
Potential Upside
12.6
5.84
7.09
12.02
8.49
8.49
21.58
2.7
11.44
9.09
Treynor Ratio
0.5182
0.1639
6.04
1.19
5.8
0.4476
1.1
(0.05)
0.3812
(0.03)
Maximum Drawdown
30.93
24.2
16.14
23.18
83.78
36.46
41.91
12.74
29.69
32.96
Variance
39.21
18.04
17.78
45.05
125.28
31.97
79.77
3.74
32.66
29.6
Market Risk Adjusted Performance
0.5282
0.1739
6.05
1.2
5.81
0.4576
1.11
(0.04)
0.3912
(0.02)
Risk Adjusted Performance
0.2134
0.0738
0.2217
0.2518
0.1578
0.1428
0.2334
(0.02)
0.1189
(0)
Skewness
0.2542
(1.03)
0.8376
0.0698
6.04
(1.20)
0.618
(2.22)
0.8572
(0.61)
Semi Deviation
4.44
4.33
2.96
4.86
3.13
5.48
5.83
N/A
4.34
N/A
Information Ratio
0.1969
0.0375
0.1956
0.2394
0.1465
0.119
0.2246
(0.09)
0.0937
(0.04)
Value At Risk
(8.00)
(4.15)
(4.35)
(8.49)
(5.62)
(5.29)
(10.81)
(2.51)
(7.43)
(5.11)
Expected Short fall
(6.36)
(2.85)
(3.57)
(6.78)
(6.92)
(4.31)
(8.94)
N/A
(4.84)
N/A
Downside Deviation
5.24
4.69
3.4
6.29
4.07
6.42
6.73
N/A
4.65
N/A
Semi Variance
19.7
18.75
8.75
23.59
9.8
30.07
34.0
N/A
18.87
N/A

Editas Medicine Competition Performance Charts

Five steps to successful analysis of Editas Medicine Competition

Editas Medicine's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Editas Medicine in relation to its competition. Editas Medicine's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Editas Medicine in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Editas Medicine's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Editas Medicine, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Editas Medicine position

In addition to having Editas Medicine in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Strategy ETFs Thematic Idea Now

Strategy ETFs
Strategy ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Strategy ETFs theme has 1459 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Strategy ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY